

ILARIS®  
(canakinumab)  
150 mg subcutaneous injection  
For the treatment of Still's disease including, Adult-Onset Still's  
Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA)

## IMPORTANT INFORMATION

**REPORTING OF SIDE EFFECTS:** If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at <http://www.mhra.gov.uk/yellowcard>  
By reporting side effects you can help provide more information on the safety of this medicine.

---

### Before canakinumab treatment

- Infections: You should not be treated with canakinumab if you have an active infection requiring medical intervention.
- Vaccinations: Talk to your doctor about any vaccinations you may need before starting treatment with canakinumab.

### During canakinumab treatment

- Risk of infections: Use of canakinumab is associated with an increased risk of infections, including serious infections.
- If you develop an infection, your canakinumab treatment might need to be interrupted. Tell your doctor immediately if you have a fever lasting longer than 3 days or other symptoms that might be due to an infection.
- Seek medical attention immediately if you develop symptoms such as:
  - prolonged fever, cough or headache, or
  - localised redness, warmth or swelling of your skin, or
  - persistent cough, weight loss and low-grade fever.
- Macrophage Activation Syndrome (MAS): Patients with Still's disease may develop a condition called macrophage (a type of white blood cell) activation syndrome (MAS), which can be life-threatening. Tell your doctor right away if your Still's disease symptoms become worse or if you have symptoms of an infection as these can be triggers of MAS. Pregnancy:
- If you received canakinumab while you were pregnant, it is important that you inform the baby's doctor or nurse before any vaccinations are given to your baby. Your baby should not receive live vaccines until at least 16 weeks after you received your last dose of canakinumab before giving birth.

---

### Treatment Indication:

Please make sure to have a LIST OF ALL MEDICATIONS you are taking when visiting a healthcare professional.

Patient's name: \_\_\_\_\_

For children: parent's/guardian's name: \_\_\_\_\_

Date of first dose of canakinumab: \_\_\_\_\_

Canakinumab dose administered: \_\_\_\_\_

Doctor's name: \_\_\_\_\_

Doctor's phone: \_\_\_\_\_